The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study.
about
Androgen receptor degradation by the proteolysis-targeting chimera ARCC-4 outperforms enzalutamide in cellular models of prostate cancer drug resistanceSmall-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugsPharmacological difference between degrader and inhibitor against oncogenic BCR-ABL kinase
P2860
The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study.
@en
The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study.
@en-gb
The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study.
@nl
type
label
The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study.
@en
The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study.
@en-gb
The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study.
@nl
prefLabel
The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study.
@en
The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study.
@en-gb
The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study.
@nl
P2093
P2860
P50
P1476
The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study.
@en
P2093
Andrew P Crew
Ashton C Lai
Craig M Crews
Daniel P Bondeson
Hanqing Dong
John Hines
Momar Toure
Saul Jaime-Figueroa
Yimin Qian
P2860
P304
P356
10.1016/J.CHEMBIOL.2017.09.009
P577
2017-10-25T00:00:00Z